Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Allyl Isothiocyanate (AITC)
Allyl Isothiocyanate · 1 trial · 1 indication
DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. The mean DBF in the ROI will be reported.
AUC0-20 is defined as the area under the curve from time 0-20 minutes. DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. AUC0-20 of mean DBF in ROI will be reported.
AUC0-60 is defined as the area under the curve from time 0-60 minutes. DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. AUC0-60 of mean DBF in ROI will be reported.
| Arm | Type | Description |
|---|---|---|
| Laser Speckle Contrast Imaging | EXPERIMENTAL | Participants receive topical Allyl Isothiocyanate (AITC) application and intradermal capsaicin application sequentially along with a placebo comparator (vehicle for AITC and vehicle for capsaicin) once every 2 weeks per protocol to perform laser speckle contrast imaging. |
| Name | Type | Description |
|---|---|---|
| Allyl Isothiocyanate (AITC) | DRUG | Topical administration |
| Capsaicin | DRUG | Intradermal administration |
| Vehicle for AITC | OTHER | Topical administration |
| Vehicle for Capsaicin | OTHER | Intradermal administration |
Inclusion Criteria: * Is in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms performed before randomization * Has a skin surface without significant skin allergies, pigmentary disorders or active dermatological conditions that may interfere...
Allyl Isothiocyanate is a small molecule compound that Merck & Company, Inc. (ticker MRK) has studied in a Phase 1 clinical trial. It was evaluated in a completed study of 12 healthy male participants in Belgium. The trial examined laser speckle contrast imaging to assess changes in chemical agent-induced skin blood flow.
Allyl Isothiocyanate is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company sponsored a Phase 1 trial of the compound in healthy volunteers.
Allyl Isothiocyanate is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 12 healthy male participants in Belgium.
Allyl Isothiocyanate has been studied in one completed Phase 1 trial, NCT06809569, titled A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420). The trial enrolled 12 healthy male volunteers in Belgium and was not randomized, blinded, or controlled.
Yes, Allyl Isothiocyanate is also known as AITC. Both names refer to the same small molecule being developed by Merck & Company, Inc. (ticker MRK).